{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:57:04Z","timestamp":1787954224332,"version":"build-2784847793"},"reference-count":13,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Capmatinib is a mesenchymal-epithelial transition (MET) inhibitor authorized for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation treatment in adult patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report a case of an elderly female with a diagnosis of metastatic NSCLC with MET exon 14 skipping mutation who developed a severe hepatotoxicity after 7 weeks under treatment with capmatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>Capmatinib was immediately discontinued. Hepatotoxicity is included as \u201cwarning and precautions\u201d in the product information sheet. The patient was admitted with severe acute hepatitis, secondary hypocoagulability and acute deterioration of renal function. She experienced a rapid worsening with a fatal outcome three days after admission. The causal relationship between capmatinib and the appearance of hepatotoxicity was determined as probable according to Naranjo's modified Karch and Lasagna's imputability algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The recognition and diagnosis of drug-induced liver injury (DILI) are often difficult and delayed. Molecularly targeted agents require careful assessment of liver function both prior to and during therapy. Capmatinib hepatotoxicity is an infrequent but severe adverse drug reaction (ADR). Prescribing information includes recommendations about liver function monitoring. The main approachment for DILI is the removal of the causative agent. Detection and communication of ADRs to the Pharmacovigilance Systems have special relevance for novel drugs, with little data in real life setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231173120","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T02:02:53Z","timestamp":1683597773000},"page":"1484-1488","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Severe hepatotoxicity during treatment with capmatinib"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-0441","authenticated-orcid":false,"given":"Carmen Mar\u00eda","family":"Valencia Soto","sequence":"first","affiliation":[{"name":"Pharmacy Service, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Mart\u00ednez Callejo","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Garc\u00eda-Avello Fern\u00e1ndez-Cueto","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Villaca\u00f1as Palomares","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Barbadillo Villanueva","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Ochagav\u00eda Sufrategui","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Francisca","family":"L\u00f3pez-Brea Piqueras","sequence":"additional","affiliation":[{"name":"Oncology Service, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valero Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"bibr1-10781552231173120","unstructured":"Personalized, genotype-directed therapy for advanced non-small cell lung cancer - UpToDate [Internet]. [cited 2022 Oct 16]. Available from: https:\/\/www-uptodate-com.scsalud.a17.csinet.es\/contents\/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer?search=Personalized, genotype-directed therapy for advanced non-small cell lung cancer&source\u2009=\u2009search_result&selectedTitle=1\u223c150&usage_type\u2009=\u2009default&display_rank=1"},{"key":"bibr2-10781552231173120","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i4.217"},{"key":"bibr3-10781552231173120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002787"},{"key":"bibr4-10781552231173120","unstructured":"Ficha t\u00e9cnica TABRECTA\u00ae (Capmatinib), Disponible en: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213591s000lbl.pdf (Acceso Octubre 2022)."},{"key":"bibr5-10781552231173120","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017 [cited 2022 Oct 16]; Available from: https:\/\/www.meddra.org\/"},{"key":"bibr6-10781552231173120","unstructured":"Centro Nacional de Farmacovigilancia y Tecnovigilancia. Centro de referencia institucional de Farmacovigilancia y Tecnovigilancia de ESSALUD anexo N\n                      o\n                      07 Instructivo para evaluaci\u00f3n de la causalidad usando el Algoritmo Karch y Lasagna modificado. (0):2\u20133."},{"key":"bibr7-10781552231173120","unstructured":"BOE.es - BOE-A-2006-13554 Ley 29\/2006, de 26 de julio, de garant\u00edas y uso racional de los medicamentos y productos sanitarios. [Internet]. [cited 2022 Oct 16]. Available from: https:\/\/www.boe.es\/eli\/es\/l\/2006\/07\/26\/29"},{"key":"bibr8-10781552231173120","unstructured":"TEJADA CIFUENTES, FRANACISCO. Hepatotoxicidad por F\u00e1rmacos.\n                      R\n                      ev Clin Med Fam [online]. 2010, vol.3, n.3 [citado 2022-10-23], pp.177-191. Disponible en: < http:\/\/scielo.isciii.es\/scielo.php?script=sci_arttext&pid=S1699-695X2010000300006&lng=es&nrm=iso> ISSN 2386-8201."},{"key":"bibr9-10781552231173120","unstructured":"Francis P, Navarro VJ. Drug Induced Hepatotoxicity. StatPearls [Internet]. 2022 Mar 18 [cited 2022 Oct 16]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557535\/"},{"key":"bibr10-10781552231173120","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01390-6"},{"key":"bibr11-10781552231173120","unstructured":"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents - UpToDate [Internet]. [cited 2022 Oct 16]. Available from: https:\/\/www-uptodate-com.scsalud.a17.csinet.es\/contents\/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease-molecularly-targeted-agents?search=Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents&source\u2009=\u2009search_result&selectedTitle=1\u223c150&usage_type\u2009=\u2009default&display_rank=1"},{"key":"bibr12-10781552231173120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.001"},{"key":"bibr13-10781552231173120","unstructured":"Acute liver failure in adults: Management and prognosis - UpToDate [Internet]. [cited 2022 Oct 16]. Available from: https:\/\/www-uptodate-com.scsalud.a17.csinet.es\/contents\/acute-liver-failure-in-adults-management-and-prognosis?search\u2009=\u2009Acute liver failure in adults: Management and prognosis&source\u2009=\u2009search_result&selectedTitle\u2009=\u20091\u223c150&usage_type\u2009=\u2009default&display_rank\u2009=\u20091"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231173120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231173120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231173120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:22Z","timestamp":1777688902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231173120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/10781552231173120"],"URL":"https:\/\/doi.org\/10.1177\/10781552231173120","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]}}}